Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer
In this MEDtalk Peter Schmid present updated data for overall survival from Impassion 130-study - a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer. This 2nd IMpassion130 interim OS analysis confirming clinically meaningful OS benefit of this treatment combination.
MEST SETE MEDtalks
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer Se hele webinar
Locally advanced or metastatic urothelial cancer remains a lethal disease with limited treatment options for patients who progress on or after platinum and/or checkpoint inhibitor (CPI). In this MEDtalk Daniel Peter Petrylak present a new streatment of urothelial cancer Enfortumab vedotin (EV) - an antibody-drugconjugate targeting Nectin-4, which is highly expressed in UC. This study demonstrate the fact, that Enfortumab vedotin have a therapy that can help people who don’t benefit from checkpoint inhibitors.